When Is the Recommended Phase 2 Dose (RP2D) Determined?

 The Recommended Phase 2 Dose (RP2D) is typically determined in Phase 1 clinical trials. In this article, I give a concise explanation of when and how the RP2D is established:

1. Phase 1 Clinical Trials:

   • The RP2D is determined during Phase 1 clinical trials, which are the initial stage of testing in humans for a new investigational drug. Phase 1 trials focus on assessing the safety, tolerability, pharmacokinetics, and, to some extent, early signs of efficacy of the drug.
   • 
     

2. Dose Escalation:

   • Phase 1 trials often involve a dose-escalation phase where small groups of participants (cohorts) are sequentially exposed to increasing doses of the investigational drug. This process helps identify the highest dose level that can be administered safely without causing unacceptable side effects.
   • 
     

3. Establishing the RP2D:

   • The RP2D is established based on the data collected during the dose-escalation phase of the Phase 1 trial. It represents the dose level at which the drug exhibits an acceptable safety profile while demonstrating the desired pharmacological activity or early signs of efficacy.
   • 
     

4. Safety and Tolerability:

   • The determination of the RP2D is heavily influenced by the evaluation of safety and tolerability data. Researchers closely monitor participants for adverse events, and the RP2D is typically set at a dose level where the incidence and severity of adverse effects are manageable and do not exceed predefined safety thresholds. Sometimes, but not always, the RP2D may be the Maximum Tolerated Dose (MTD) that is determined in the dose escalation phase.
   • 
     

5. Pharmacokinetics and Pharmacodynamics:

   • Additionally, pharmacokinetic (how the drug is absorbed, distributed, metabolized, and excreted) and pharmacodynamic (the drug's effect on the body) data play a role in establishing the RP2D. The goal is to ensure that the drug is reaching therapeutic levels in the body and having the intended biological effect.
   • 
     

6. Dose Expansion Cohorts (Optional but frequently done):

   • In some cases, after the initial dose escalation, Phase 1 trials may include dose expansion cohorts. These cohorts involve enrolling additional participants at the determined RP2D to gather more safety and efficacy data.
   • 
     

7. RP2D and Phase 2:

   • Once the RP2D is established, it serves as the recommended dose to be used in subsequent Phase 2 clinical trials. Phase 2 trials involve larger groups of patients and further assess the drug's efficacy in treating the target condition.

In summary, the Recommended Phase 2 Dose (RP2D) is determined in Phase 1 clinical trials through a systematic process of dose escalation and careful evaluation of safety, tolerability, pharmacokinetics, and early signs of efficacy. The RP2D is a critical reference point for guiding the dosing of the investigational drug in subsequent Phase 2 trials and beyond in the drug development process.